Abstract
Purpose: Sorafenib is the only currently approved systemic therapy for advanced hepatocellular carcinoma (HCC). We aimed to evaluate the safety and ef......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
